Experimental hypertension and other responses to 18-hydroxy-deoxycorticosterone treatment in the rat.
Young female unilaterally nephrectomized, salt-loaded, Sprague-Dawley rats were treated with 200 microgram or 1 mg 18-hydroxy-deoxycorticosterone-21-acetate (18-OH-DOCA) in oil daily, and a group of kidney-intact animals on a normal salt intake was given 2 mg/day. The hormone was not found to increase saline consumption, increase urinary potassium or kallikrein excretion, or depress serum renin activity or potassium concentration. Slight hypertension did develop at 3 weeks in salt-loaded rats on the lowest dose, but this was neither increased by higher dosage or longer treatment, nor reflected by increased heart or kidney weight. The effect of 40-mg pellet implantation of DOCA and 18-OH-DOCA was then compared in unilaterally nephrectomized, salt-loaded, female Fischer 344 rats. The former caused increased saline consumption, hypertension, hypokalemia, and heart and kidney enlargement, whereas 18-OH-DOCA did not. Thus, the hypertensogenic potency of 18-OH-DOCA is, at best, a reflection of its known, very weak, mineralocorticoid activity.
D015070:18-Hydroxydesoxycorticosterone / Q000494:pharmacology*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003900:Desoxycorticosterone / Q000031:analogs & derivatives*; D004326:Drinking / Q000187:drug effects; D005260:Female; D006973:Hypertension / Q000139:chemically induced / Q000503:physiopathology*; D007610:Kallikreins / Q000378:metabolism; D009392:Nephrectomy; D009929:Organ Size / Q000187:drug effects; D011188:Potassium / Q000378:metabolism; D051381:Rats; D012083:Renin / Q000097:blood; D012964:Sodium / Q000378:metabolism
D015070:18-Hydroxydesoxycorticosterone; D003900:Desoxycorticosterone; D012964:Sodium; D007610:Kallikreins; D012083:Renin; D011188:Potassium